{"id":9404,"date":"2025-12-28T22:22:42","date_gmt":"2025-12-28T13:22:42","guid":{"rendered":"https:\/\/japanir.jp\/en\/company\/company-4534\/"},"modified":"2026-10-04T16:33:53","modified_gmt":"2026-10-04T07:33:53","slug":"company-4534","status":"publish","type":"company","link":"https:\/\/japanir.jp\/en\/company\/company-4534\/","title":{"rendered":"MOCHIDA PHARMACEUTICAL CO"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"4534","DATE":"2025-12-26","longName":"Mochida Pharmaceutical Co., Ltd.","company_name_ja":"","fullTimeEmployees":1479,"address":"","phone":"","website":"https:\/\/www.mochida.co.jp","industry":"Drug Manufacturers - Specialty & Generic","sector":"Healthcare","regularMarketPrice":3445,"financialCurrency":"","marketCap":122126,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":222.96000000000001,"epsForward":0,"bookValue":0,"totalRevenue":116951000000,"OperatingIncome":10147000000,"operatingMargins":8.6799999999999997,"NetIncome":7903000000,"profitMargins":6.7599999999999998,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":5.6299999999999999,"recommendationMean":0,"recommendationKey":"none","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"{\"success\": true, \"fetched_at\": \"2026-10-01T06:24:29.670818\", \"ticker\": \"4534\", \"ticker_full\": \"4534.T\", \"company_name\": \"MOCHIDA PHARMACEUTICAL CO\", \"analyst_recommendations\": {\"has_data\": true, \"recommendation_key\": \"none\", \"recommendation_mean\": null, \"total_analysts\": null, \"strong_buy\": null, \"buy\": null, \"hold\": null, \"sell\": null, \"strong_sell\": null}, \"target_prices\": {\"has_data\": true, \"current\": 3175.0, \"high\": null, \"low\": null, \"mean\": null, \"median\": null}, \"earnings_dates\": {\"has_data\": true, \"next_earnings\": null, \"future_count\": 0, \"past_earnings\": [{\"date\": \"2016-01-31\", \"eps_estimate\": 101.11, \"eps_actual\": 90.22, \"surprise_pct\": -10.78}, {\"date\": \"2015-07-30\", \"eps_estimate\": 43.46, \"eps_actual\": 80.56, \"surprise_pct\": 85.36}, {\"date\": \"2015-05-14\", \"eps_estimate\": 28.84, \"eps_actual\": 26.65, \"surprise_pct\": -7.6}, {\"date\": \"2015-01-29\", \"eps_estimate\": 63.24, \"eps_actual\": 84.87, \"surprise_pct\": 34.2}, {\"date\": \"2014-10-30\", \"eps_estimate\": 76.62, \"eps_actual\": 29.29, \"surprise_pct\": -61.77}]}, \"shareholders\": {\"has_data\": true, \"insider_pct\": 36.33, \"institution_pct\": 14.01, \"major_holders\": [{\"label\": \"\", \"value\": 36.33}, {\"label\": \"\", \"value\": 14.01}, {\"label\": \"\", \"value\": 22.01}, {\"label\": \"\", \"value\": 67.0}], \"institutional_holders\": [], \"mutualfund_holders\": [{\"holder\": \"Vanguard International Stock Index-Total Intl Stock Indx\", \"shares\": 324658, \"date_reported\": \"2024-07-31\", \"pct_held\": 0.87, \"pct_change\": 0.0, \"value\": 1030789150}, {\"holder\": \"Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund\", \"shares\": 193862, \"date_reported\": \"2024-09-30\", \"pct_held\": 0.52, \"pct_change\": 0.0, \"value\": 615511850}, {\"holder\": \"iShares Core MSCI EAFE ETF\", \"shares\": 134900, \"date_reported\": \"2024-09-30\", \"pct_held\": 0.36, \"pct_change\": 0.0, \"value\": 428307500}, {\"holder\": \"iShares MSCI EAFE Small Cap ETF\", \"shares\": 66800, \"date_reported\": \"2024-09-30\", \"pct_held\": 0.18, \"pct_change\": -1.62, \"value\": 212090000}, {\"holder\": \"Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index\", \"shares\": 63900, \"date_reported\": \"2024-07-31\", \"pct_held\": 0.17, \"pct_change\": 9.42, \"value\": 202882500}, {\"holder\": \"iShares Core MSCI Total International Stock ETF\", \"shares\": 62800, \"date_reported\": \"2024-09-30\", \"pct_held\": 0.17, \"pct_change\": 0.0, \"value\": 199390000}, {\"holder\": \"DFA Japanese Small Company Series\", \"shares\": 51698, \"date_reported\": \"2024-07-31\", \"pct_held\": 0.14, \"pct_change\": -23.97, \"value\": 164141150}, {\"holder\": \"DFA International Core Equity Portfolio\", \"shares\": 52098, \"date_reported\": \"2024-07-31\", \"pct_held\": 0.14, \"pct_change\": 10.15, \"value\": 165411150}, {\"holder\": \"Schwab Strategic Tr-Schwab Fundamental Intl Small Company Idx ETF\", \"shares\": 51012, \"date_reported\": \"2024-08-31\", \"pct_held\": 0.14, \"pct_change\": -5.89, \"value\": 161963100}, {\"holder\": \"Schwab Strategic Tr-Schwab International Small Cap Equity ETF\", \"shares\": 43625, \"date_reported\": \"2024-08-31\", \"pct_held\": 0.12, \"pct_change\": -1.12, \"value\": 138509375}]}}","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatologists, psychiatry, and gastroenterological, including Realda and Collagen for the treatment of ulcerative colitis; Goofis and Movicol for the treatment of chronic constipation; interstitial pulmonary hypertension for the treatment of pulmonary arterial hypertension; Treprospermid, for pulmonary hypertension associated with ulcerative lung disease; Uris, for gout and hyperuricemia; and Clorox, for ulcerative colitis; Epadel for hyperlipidemia and obstructive arteriosclerosis; Treprost for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Atelec, a calcium channel blocker antihypertensive drug; Heparin Na anticoagulants; and Onboard, ulcerative colitis and Crohn's disease treatment agents. In addition, it develops medical devices, including dMD-002, which is used for the treatment of cavernous nerve injury; and dMD-003 for adhesion prevention material. Further, the company engages in the development, production, distribution, sale, and marketing of skincare products, as well as academic research and marketing. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Shinjuku, Japan.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":82.5,"get_dividend_history_year2":80,"get_dividend_history_year3":80,"get_dividend_history_year4":80,"get_dividend_history_year5":90,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-10-04T06:12:05.885493\", \"ticker\": \"4534\", \"ticker_full\": \"4534.T\", \"company_name\": \"MOCHIDA PHARMACEUTICAL CO\", \"company_info\": {\"name_en\": \"MOCHIDA PHARMACEUTICAL CO\", \"long_name\": \"Mochida Pharmaceutical Co., Ltd.\", \"sector\": \"Healthcare\", \"industry\": \"Drug Manufacturers - Specialty & Generic\", \"website\": \"https:\/\/www.mochida.co.jp\", \"employees\": 1479, \"country\": \"Japan\", \"city\": \"Shinjuku\", \"address\": \"7, Yotsuya 1-chome\", \"description\": \"Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatologists, psychiatry, and gastroenterological, including Realda and Collagen for the treatment of ulcerative colitis; Goofis and Movicol for the treatment of chronic constipation; interstitial pulmonary hypertension for the treatment of pulmonary arterial hypertension; Treprospermid, for pulmonary hypertension associated with ulcerative lung disease; Uris, for gout and hyperuricemia; and Clorox, for ulcerative colitis; Epadel for hyperlipidemia and obstructive arteriosclerosis; Treprost for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Atelec, a calcium channel blocker antihypertensive drug; Heparin Na anticoagulants; and Onboard, ulcerative colitis and Crohn's disease treatment agents. In addition, it develops medical devices, including dMD-002, which is used for the treatment of cavernous nerve injury; and dMD-003 for adhesion prevention material. Further, the company engages in the development, production, distribution, sale, and marketing of skincare products, as well as academic research and marketing. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Shinjuku, Japan.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 3170.5, \"deviation\": -2.54, \"trend\": \"down\"}, \"ma_25\": {\"ma_value\": 3207.51, \"deviation\": -3.66, \"trend\": \"down\"}, \"ma_75\": {\"ma_value\": 3156.66, \"deviation\": -2.11, \"trend\": \"down\"}, \"ma_200\": {\"ma_value\": 3353.6, \"deviation\": -7.86, \"trend\": \"down\"}}, \"financials\": {\"years\": [{\"year\": 2026, \"revenue\": 116951000000.0, \"revenue_fmt\": \"\u00a51170\u5104\", \"gross_profit\": 56260000000.0, \"gross_profit_fmt\": \"\u00a5563\u5104\", \"operating_income\": 10147000000.0, \"operating_income_fmt\": \"\u00a5101\u5104\", \"ebit\": 11243000000.0, \"ebit_fmt\": \"\u00a5112\u5104\", \"net_income\": 7903000000.0, \"net_income_fmt\": \"\u00a579\u5104\", \"eps\": 222.96, \"operating_margin\": 8.68, \"total_assets\": 182720000000.0, \"total_assets_fmt\": \"\u00a51827\u5104\", \"total_equity\": 140324000000.0, \"total_equity_fmt\": \"\u00a51403\u5104\", \"total_debt\": 10000000000.0, \"total_debt_fmt\": \"\u00a5100\u5104\", \"total_cash\": 28064000000.0, \"total_cash_fmt\": \"\u00a5281\u5104\", \"equity_ratio\": 76.8, \"de_ratio\": 0.07, \"current_ratio\": 4.29, \"operating_cf\": -7350000000.0, \"operating_cf_fmt\": \"-\u00a574\u5104\", \"investing_cf\": -16848000000.0, \"investing_cf_fmt\": \"-\u00a5168\u5104\", \"financing_cf\": 7033000000.0, \"financing_cf_fmt\": \"\u00a570\u5104\", \"free_cf\": -10045000000.0, \"free_cf_fmt\": \"-\u00a5100\u5104\", \"net_margin\": 6.76, \"roe\": 5.63, \"roa\": 4.33}, {\"year\": 2025, \"revenue\": 105159000000.0, \"revenue_fmt\": \"\u00a51052\u5104\", \"gross_profit\": 53787000000.0, \"gross_profit_fmt\": \"\u00a5538\u5104\", \"operating_income\": 8126000000.0, \"operating_income_fmt\": \"\u00a581\u5104\", \"ebit\": 8055000000.0, \"ebit_fmt\": \"\u00a581\u5104\", \"net_income\": 5685000000.0, \"net_income_fmt\": \"\u00a557\u5104\", \"eps\": 160.36, \"operating_margin\": 7.73, \"total_assets\": 160121000000.0, \"total_assets_fmt\": \"\u00a51601\u5104\", \"total_equity\": 130693000000.0, \"total_equity_fmt\": \"\u00a51307\u5104\", \"total_debt\": 0.0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 45154000000.0, \"total_cash_fmt\": \"\u00a5452\u5104\", \"equity_ratio\": 81.62, \"de_ratio\": 0.0, \"current_ratio\": 4.81, \"operating_cf\": 9354000000.0, \"operating_cf_fmt\": \"\u00a594\u5104\", \"investing_cf\": 17355000000.0, \"investing_cf_fmt\": \"\u00a5174\u5104\", \"financing_cf\": -2865000000.0, \"financing_cf_fmt\": \"-\u00a529\u5104\", \"free_cf\": 7194000000.0, \"free_cf_fmt\": \"\u00a572\u5104\", \"net_margin\": 5.41, \"roe\": 4.35, \"roa\": 3.55}, {\"year\": 2024, \"revenue\": 102885000000.0, \"revenue_fmt\": \"\u00a51029\u5104\", \"gross_profit\": 52070000000.0, \"gross_profit_fmt\": \"\u00a5521\u5104\", \"operating_income\": 5803000000.0, \"operating_income_fmt\": \"\u00a558\u5104\", \"ebit\": 6162000000.0, \"ebit_fmt\": \"\u00a562\u5104\", \"net_income\": 4547000000.0, \"net_income_fmt\": \"\u00a545\u5104\", \"eps\": 126.8, \"operating_margin\": 5.64, \"total_assets\": 158800000000.0, \"total_assets_fmt\": \"\u00a51588\u5104\", \"total_equity\": 127965000000.0, \"total_equity_fmt\": \"\u00a51280\u5104\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 33290000000.0, \"total_cash_fmt\": \"\u00a5333\u5104\", \"equity_ratio\": 80.58, \"de_ratio\": 0.0, \"current_ratio\": 4.47, \"operating_cf\": -7480000000.0, \"operating_cf_fmt\": \"-\u00a575\u5104\", \"investing_cf\": 74000000.0, \"investing_cf_fmt\": \"\u00a574.0M\", \"financing_cf\": -6393000000.0, \"financing_cf_fmt\": \"-\u00a564\u5104\", \"free_cf\": -9776000000.0, \"free_cf_fmt\": \"-\u00a598\u5104\", \"net_margin\": 4.42, \"roe\": 3.55, \"roa\": 2.86}, {\"year\": 2023, \"revenue\": 103261000000.0, \"revenue_fmt\": \"\u00a51033\u5104\", \"gross_profit\": 55114000000.0, \"gross_profit_fmt\": \"\u00a5551\u5104\", \"operating_income\": 8507000000.0, \"operating_income_fmt\": \"\u00a585\u5104\", \"ebit\": 9044000000.0, \"ebit_fmt\": \"\u00a590\u5104\", \"net_income\": 6649000000.0, \"net_income_fmt\": \"\u00a566\u5104\", \"eps\": 178.93, \"operating_margin\": 8.24, \"total_assets\": 158831000000.0, \"total_assets_fmt\": \"\u00a51588\u5104\", \"total_equity\": 126773000000.0, \"total_equity_fmt\": \"\u00a51268\u5104\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 47010000000.0, \"total_cash_fmt\": \"\u00a5470\u5104\", \"equity_ratio\": 79.82, \"de_ratio\": 0.0, \"current_ratio\": 4.31, \"operating_cf\": 7297000000.0, \"operating_cf_fmt\": \"\u00a573\u5104\", \"investing_cf\": -2949000000.0, \"investing_cf_fmt\": \"-\u00a529\u5104\", \"financing_cf\": -6884000000.0, \"financing_cf_fmt\": \"-\u00a569\u5104\", \"free_cf\": 5131000000.0, \"free_cf_fmt\": \"\u00a551\u5104\", \"net_margin\": 6.44, \"roe\": 5.24, \"roa\": 4.19}, {\"year\": 2022, \"revenue\": 0, \"revenue_fmt\": \"N\/A\", \"gross_profit\": 0, \"gross_profit_fmt\": \"N\/A\", \"operating_income\": 0, \"operating_income_fmt\": \"N\/A\", \"ebit\": 0, \"ebit_fmt\": \"N\/A\", \"net_income\": 0, \"net_income_fmt\": \"N\/A\", \"eps\": 0, \"operating_margin\": 0, \"total_assets\": 0, \"total_assets_fmt\": \"N\/A\", \"total_equity\": 0, \"total_equity_fmt\": \"N\/A\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 0, \"total_cash_fmt\": \"N\/A\", \"equity_ratio\": 0, \"de_ratio\": 0, \"current_ratio\": 0, \"operating_cf\": 0, \"operating_cf_fmt\": \"N\/A\", \"investing_cf\": 0, \"investing_cf_fmt\": \"N\/A\", \"financing_cf\": 0, \"financing_cf_fmt\": \"N\/A\", \"free_cf\": 0, \"free_cf_fmt\": \"N\/A\", \"net_margin\": 0, \"roe\": 0, \"roa\": 0}], \"has_data\": true}, \"dividends\": {\"history\": [{\"year\": 2022, \"amount\": 90.0}, {\"year\": 2023, \"amount\": 80.0}, {\"year\": 2024, \"amount\": 80.0}, {\"year\": 2025, \"amount\": 80.0}, {\"year\": 2026, \"amount\": 82.5}], \"latest\": 42.5, \"has_data\": true}}","ma_5_value":0,"ma_5_deviation":0,"ma_5_trend":"","ma_25_value":0,"ma_25_deviation":0,"ma_25_trend":"","ma_75_value":0,"ma_75_deviation":0,"ma_75_trend":"","ma_200_value":0,"ma_200_deviation":0,"ma_200_trend":"","previousClose":0,"open":0,"dayHigh":0,"dayLow":0,"volume":0,"averageVolume":0,"revenueGrowth":0},"sector":[],"class_list":["post-9404","company","type-company","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MOCHIDA PHARMACEUTICAL CO - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4534\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4534\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4534\/\",\"name\":\"MOCHIDA PHARMACEUTICAL CO - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2025-12-28T13:22:42+00:00\",\"dateModified\":\"2026-10-04T07:33:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4534\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4534\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4534\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MOCHIDA PHARMACEUTICAL CO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MOCHIDA PHARMACEUTICAL CO - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4534\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4534\/","url":"https:\/\/japanir.jp\/en\/company\/company-4534\/","name":"MOCHIDA PHARMACEUTICAL CO - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2025-12-28T13:22:42+00:00","dateModified":"2026-10-04T07:33:53+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4534\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4534\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4534\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"MOCHIDA PHARMACEUTICAL CO"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company\/9404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/company"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=9404"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=9404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}